MED Bio
A private equity fund outside venture scope, shown because its manager is on the venture graph.
Nothing material in the last 365 days.
- Vintage
- unknownno dated first sale or first report yet
- Target
- unknownnot announced
- First close
- unknownnever inferred from a Form D
- Final close
- unknownonly from an announcement or an LP disclosure
- Announced size
- unknown
- Form D offering
- unknownwhat may be sold, not what was raised
- Form D sold
- unknown
- First sale
- unknown
- Reported GAV
- $156Mon the Form ADV filed Mar 31, 2026; the fund's assets, never its size or dry powder
- Owners (ADV)
- 38
- Reported on ADV
- Mar 31, 2026 to Mar 31, 2026
LifecycleUnknown
| Filed | Type | Gross asset value | Owners | Min. investment | Adviser-owned | Audit | |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Private Equity Fund | $156M | 38 | $5.9M | 1% |
- AuditorFORVIS, LLP · LYON, FranceForm ADV filed Mar 31, 2026 reports.adviserinfo.sec.gov
- AdministratorGrant Thornton · PARIS, FranceForm ADV filed Mar 31, 2026 reports.adviserinfo.sec.gov
- CustodianCACEIS BANK FRANCE S.A. · PARIS, FranceForm ADV filed Mar 31, 2026 reports.adviserinfo.sec.gov
- Mar 31, 2026MED Bio first reported on Form ADV by Archimed (Private Equity Fund), GAV $156,117,181Fund first reported on Form ADV Inference Form ADV
Every observation on this vehicle
Relationships across DFX
on 2 other DFX graphs
MED Bio is the same institution as 2 records in Private Equity and RIA and Wealth.
DFX found 2 relationships across 2 datasets
Which record it is in each graph, what it is called there, and how the two were matched.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Checking your plan…
Record history
- Fund first reported on ADV2026-03-31source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.